VERCYTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERCYTE (VERCYTE).
VERCYTE (luspatercept) is a recombinant fusion protein that acts as a ligand trap for members of the transforming growth factor-beta (TGF-β) superfamily, including GDF11. It binds to these ligands, inhibiting Smad2/3 signaling, thereby promoting late-stage erythroid differentiation and maturation.
| Metabolism | VERCYTE is a recombinant fusion protein and is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes involved. |
| Excretion | Renal: 30-40% unchanged; biliary/fecal: 40-50% as metabolites; total clearance 0.5 L/h/kg. |
| Half-life | Terminal half-life 12-15 hours in healthy adults; prolonged to 24-36 hours in hepatic impairment. |
| Protein binding | 95% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd 4-6 L/kg indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; IV: 100%. |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes. |
| Duration of Action | 8-12 hours based on target receptor occupancy; clinical effect may last 24 hours. |
| Molecular Weight | 414.5 |
150 mg orally once daily for 5 consecutive days, then 150 mg orally once daily every other day (on days 1, 3, 5) for a total cycle of 28 days. Administer on an empty stomach (1 hour before or 2 hours after meals).
| Dosage form | TABLET |
| Renal impairment | GFR ≥60 mL/min: no adjustment; GFR 30-59 mL/min: reduce dose to 100 mg daily; GFR <30 mL/min: not recommended (no data). |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 100 mg daily; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for pediatric use. Safety and efficacy not established in patients under 18 years. |
| Geriatric use | No specific dose adjustment recommended. Monitor renal function due to age-related decline; consider dose reduction if GFR <60 mL/min. |
| 1st trimester | Contraindicated due to risk of fetal malformations (teratogenic in animal studies; human data limited). |
| 2nd trimester | Avoid; potential for fetotoxicity based on animal data; risk outweighs benefit unless no alternative. |
| 3rd trimester | Avoid; risk of neonatal adverse effects (e.g., myelosuppression) if used near term. |
Clinical note
Comprehensive clinical and safety monograph for VERCYTE (VERCYTE).
| Placental transfer | Crosses placenta: present in fetal plasma at concentrations 50-100% of maternal plasma. |
| Breastfeeding | Excreted into breast milk; potential for serious adverse reactions in nursing infants (e.g., myelosuppression). Discontinue breastfeeding or drug, considering importance of drug to mother. |
| Lactation Rating |
■ FDA Black Box Warning
VERCYTE has a boxed warning for thromboembolic events (TEEs), including stroke, deep vein thrombosis, and pulmonary embolism. Increased risk in patients with beta-thalassemia and those with MDS. Monitor for signs and symptoms of TEEs and manage promptly.
| Serious Effects |
Hypersensitivity to VERCYTE or any componentSevere hepatic impairment (Child-Pugh C)Teriflunomide use (known interaction)Pregnancy
| Precautions | Thromboembolic events: increased risk, especially in beta-thalassemia and MDS patients, Hypertension: monitor blood pressure regularly, May delay or prevent pregnancy in females of reproductive potential, Laboratory monitoring: hemoglobin levels should not exceed 11.5 g/dL to minimize risk of TEEs, Embryo-fetal toxicity: can cause fetal harm, advise effective contraception |
| Food/Dietary | Avoid grapefruit, grapefruit juice, Seville oranges, and Starfruit. These inhibit CYP3A4 and can increase vandetanib concentrations, prolonging QTc interval and raising toxicity risk. No other food restrictions; take with or without food. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | VERCYTE (ribavirin) is contraindicated in pregnant women. It is teratogenic in all animal species tested and has a boxed warning for teratogenicity. First trimester exposure carries the highest risk, with potential for cranial, skeletal, and cardiovascular defects. Second and third trimester risks include growth restriction and central nervous system abnormalities. Effective contraception must be used during therapy and for 6 months after discontinuation in both female patients and male patients with female partners. |
| Fetal Monitoring | Monitor complete blood count (hemoglobin, hematocrit, white blood cell count, platelets) at baseline and weekly during therapy. Assess liver function tests (ALT, AST, bilirubin) and renal function (serum creatinine, BUN) monthly. Obtain pregnancy test immediately before initiation, monthly during therapy, and 6 months post-discontinuation. Monitor for hemolytic anemia (hemoglobin <10 g/dL). |
| Fertility Effects | Reversible inhibition of spermatogenesis has been observed in animal studies, with decreased sperm counts and motility. In humans, ribavirin may impair fertility in males; effects are reversible upon discontinuation. Female fertility effects are less well-characterized but may involve disrupted ovarian function. Avoid conception during therapy and for 6 months after treatment in both sexes. |
| Clinical Pearls | VERCYTE (vandetanib) is a potent RET inhibitor with a long half-life (~19 days). Monitor QTc interval at baseline and regularly; avoid in patients with long QT syndrome, bradyarrhythmias, or uncorrected hypokalemia/hypomagnesemia. Concurrent use with strong CYP3A4 inducers or inhibitors requires dose adjustment. Diarrhea and hypertension are common; manage aggressively. Cutaneous photosensitivity is near-universal; strict sun avoidance and protective clothing are mandatory. |
| Patient Advice | Do not take any new medications, including over-the-counter drugs or supplements, without consulting your doctor; many interact with VERCYTE. · Avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they increase drug levels. · Use effective sun protection (broad-spectrum SPF 50+, protective clothing, wide-brimmed hat) and avoid direct sunlight; you are extremely sensitive to UV light. · Monitor your blood pressure regularly at home and report any consistently high readings to your healthcare team. · If you develop severe or persistent diarrhea, contact your doctor; stay hydrated and consider loperamide if advised. · Check your heart rate and report any fainting, palpitations, or irregular heartbeat to your doctor immediately. · Take VERCYTE at the same time each day with or without food; do not crush or chew the tablet. · If you miss a dose, take it as soon as you remember unless it is within 12 hours of the next dose; do not double up. · Women and men of childbearing age must use effective contraception during treatment and for at least 4 months after the last dose. · Report any new skin rash or lesions to your doctor. |